Teachers Retirement System of The State of Kentucky Has $6.62 Million Holdings in Illumina, Inc. (NASDAQ:ILMN)

Teachers Retirement System of The State of Kentucky grew its holdings in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 12.4% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 50,744 shares of the life sciences company's stock after acquiring an additional 5,612 shares during the quarter. Teachers Retirement System of The State of Kentucky's holdings in Illumina were worth $6,618,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of the business. Industrial Alliance Investment Management Inc. purchased a new position in shares of Illumina during the second quarter worth $34,000. Massmutual Trust Co. FSB ADV raised its stake in shares of Illumina by 65.1% during the 3rd quarter. Massmutual Trust Co. FSB ADV now owns 426 shares of the life sciences company's stock valued at $56,000 after buying an additional 168 shares during the last quarter. Itau Unibanco Holding S.A. purchased a new position in shares of Illumina during the 2nd quarter valued at about $61,000. Private Trust Co. NA boosted its stake in shares of Illumina by 81.2% in the third quarter. Private Trust Co. NA now owns 473 shares of the life sciences company's stock worth $62,000 after buying an additional 212 shares during the last quarter. Finally, Mizuho Securities Co. Ltd. acquired a new stake in Illumina during the second quarter worth about $63,000. Hedge funds and other institutional investors own 89.42% of the company's stock.

Illumina Price Performance

Shares of ILMN stock traded down $2.56 during mid-day trading on Friday, hitting $143.87. 1,808,511 shares of the stock traded hands, compared to its average volume of 2,009,685. The company has a debt-to-equity ratio of 0.94, a quick ratio of 1.85 and a current ratio of 2.43. The firm has a market cap of $22.82 billion, a price-to-earnings ratio of -14.70 and a beta of 1.11. The company's 50-day simple moving average is $144.22 and its 200-day simple moving average is $128.02. Illumina, Inc. has a twelve month low of $100.08 and a twelve month high of $156.66.

Illumina (NASDAQ:ILMN - Get Free Report) last issued its quarterly earnings results on Monday, November 4th. The life sciences company reported $1.14 earnings per share for the quarter, beating analysts' consensus estimates of $0.88 by $0.26. Illumina had a negative net margin of 36.10% and a positive return on equity of 7.29%. The company had revenue of $1.08 billion during the quarter, compared to the consensus estimate of $1.08 billion. During the same period in the prior year, the company earned $0.33 EPS. Illumina's revenue was down 3.5% on a year-over-year basis. As a group, equities research analysts expect that Illumina, Inc. will post 4.11 earnings per share for the current year.

Wall Street Analysts Forecast Growth

ILMN has been the topic of a number of analyst reports. Citigroup cut Illumina from a "buy" rating to a "neutral" rating and dropped their target price for the company from $190.00 to $165.00 in a research report on Wednesday. Daiwa America raised Illumina to a "strong-buy" rating in a research note on Friday, August 16th. Canaccord Genuity Group boosted their price target on shares of Illumina from $130.00 to $145.00 and gave the company a "hold" rating in a research report on Tuesday, November 5th. UBS Group raised their price objective on shares of Illumina from $133.00 to $145.00 and gave the stock a "neutral" rating in a research report on Tuesday, November 5th. Finally, Robert W. Baird boosted their target price on shares of Illumina from $124.00 to $139.00 and gave the company a "neutral" rating in a report on Wednesday, November 6th. Nine investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $165.86.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.